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Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are prototypical motor neuron diseases that result in progressive
weakness as a result of motor neuron dysfunction and death. Though much work has been done in both diseases to identify the cellular
mechanisms of motor neuron dysfunction, once motor neurons have died, one of potential therapies to restore function would be through the use
of cellular transplantation. In this review, we discuss potential strategies whereby cellular therapies, including the use of stem cells, neural
progenitors and cells engineered to secrete trophic factors, may be used in motor neuron diseases. We review pre-clinical data in rodents with each
of these approaches and discuss advances and regulatory issues regarding the use of cellular therapies in human motor neuron diseases.
© 2006 Elsevier B.V. All rights reserved.Keywords: Amyotrophic lateral sclerosis; Spinal muscular atrophy; Motor neuron disease; Stem cell; Transplantation; Spinal cord; Paralysis1. Different motor neuron disorders may require different
approaches
Though amyotrophic lateral sclerosis (ALS) and spinal
muscular atrophy (SMA) share several clinical and pathologic
features, important distinctions between them do exist, and
appreciation of these distinctions may inform attempts to
develop cellular therapies for motor neuron diseases. SMA is a
common autosomal recessive disorder that usually presents with
a spectrum of clinical severity ranging from infantile onset in
children with severe hypotonia, difficulty feeding and early
lethality to a milder adult onset form [1]. Pathologically, SMA is
characterized by loss of lower motor neurons in the spinal cord
and by abnormal morphology of distal motor axons [2,3].
Genetic analyses have determined that the survival motor
neuron (SMN1) gene is mutated or deleted in the vast majority
of patients [4]. Although it is unclear why deletion of a gene⁎ Corresponding author. Department of Neurology, Johns Hopkins University,
Pathology 627C, 600 North Wolfe Street, Baltimore, MD 21287, USA.
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doi:10.1016/j.bbadis.2006.06.004whose protein is ubiquitously expressed results specifically in
motor neuron death, it is most likely that SMA is largely a cell-
autonomous disorder. Specifically, the most likely hypothesis is
that lower motor neurons have a unique requirement for SMN
and that reductions in this protein induce motor neuron death
with little contribution from other cell types.
ALS, by contrast, can be either a sporadic or genetic disorder
that is characterized by death and dysfunction of motor neurons
in the cerebral cortex, brain stem, and spinal cord. In addition to
the challenge of replacing damaged upper motor neurons not
involved in SMA, there is widespread alteration in the
morphology and function of other cell types throughout the
central and peripheral nervous system in ALS. Indeed, it is now
clear that multiple distinct cells and biochemical pathways
influence motor neuron death in ALS [5].
Using these two prototypic motor neuron diseases, it is
possible to consider several cellular strategies to influence
clinical disease. In both ALS and SMA, direct replacement of
motor neuron circuits may be the most challenging task because
it requires transplanted cells not only to become motor neurons
and be recognized and connected by host central nervous
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form neuromuscular junctions with skeletal muscle. In ALS but
not SMA, replacement of corticospinal tract neurons is required
to restore motor circuits. Other strategies in ALS would be to
use the stem cells to deliver factors that modulate the cell injury
pathways or to alter the function of non-neuronal cells (i.e.,
microglia or astrocytes). In both ALS and SMA, it may be
possible to utilize cellular therapies to deliver trophic factors to
motor neurons in order to potentially overcome the cell injury
cascades.
2. Overview of stem cells
Stem cells are defined as precursor cells that have the
capacity to self-renew and to generate multiple mature cell
types. Totipotency is defined as the ability to differentiate into
any cell type, pluripotency as the ability to differentiate into
many but not all cell types, and unipotency as the ability to
differentiate into only a single cell type. Embryonic stem (ES)
cells are derived from the inner cell mass of cultured embryos at
the blastocyst stage. These cells are pluripotent as defined by
the ability to form many mature cell types in tissue culture or by
the generation of chimeric mice on injection into recipient
blastocysts [6]. Progenitor cells have a more limited capacity for
self-renewal and a more restricted differentiation potential. (i.e.,
are often unipotent) [7]. Dedifferentiation refers to the ability of
cells to acquire a more primitive (i.e., pluripotent) state after
assuming a mature, post-mitotic identity. This process, if it
occurs at all, would require re-entry into the cell cycle and may
be a precedent of transdifferentiation. Transdifferentiation,
which is also a controversial concept, is a process whereby
one cell type committed to and progressing along a specific
developmental lineage switches into another cell type of a
different lineage through genetic reprogramming.
Several sources of stem cells exist, including blastocyst-stage
embryos and fetal and adult tissues. Endogenous stem cells exist
within the adult nervous system of higher mammals, and
recently, several groups have successfully isolated and expanded
human stem cells from specific regions of the brain and spinal
cord. The biological underpinning of the use of stem cells in
neurodegenerative disorders is that stem cells have the potential
to differentiate into mature cell types by responding to
developmental cues appropriate to that cell type. These
developmental cues may be provided in a stochastic manner
within clusters of differentiating stem cells or in an inductive
way by surrounding cells or tissues in vivo. However,
researchers have recently begun to develop strategies to
specifically direct the differentiation of stem cells toward a
particular mature cell lineage in vitro. This is a critical advance
in stem cell biology since it allows researchers to generate a
potentially inexhaustible supply of relatively pure, committed,
or fully-differentiated mature cell types. These cells can then be
utilized in biological studies in vitro or can be applied to the
study of disease. However, a necessary corollary is that an
understanding of the developmental processes for inducing a
particular lineage is critical to their use. Since many of these
processes remain poorly understood, the full potential of stemcells in treating disease will only be realized with a more
complete understanding of developmental biology.
3. Types of stem cells
Neural stem cells (NSCs) exist within multiple regions of the
nervous system and it has been possible to isolate and expand
multipotent cells from multiple regions of the fetal or adult
nervous system [8,9]. Adult NSCs divide less frequently than
their embryonic counterparts and therefore may be more
difficult to expand into large cultures required for clinical
applications [10,11]. However, adult NSCs have been shown to
be pluripotent, to efficiently respond to local environmental
cues in order to differentiate into mature cell types and to
integrate with host neural cells in several cases [12,13].
Olfactory ensheathing cells have also been shown to be a
source of multipotent stem cells within the developing and adult
nervous system and may be another source of stem cells for
autologous transplant-mediated repair of CNS injury models
[14–18].
Earlier work, much of which was done in rodents, has
recently been extended to isolate and expand human NSCs from
multiple distinct regions of the brain and spinal cord [19,20].
These cells can be expanded and subjected to a cell sorting
method based on cell-type specific promoter activation linked to
a green fluorescent protein (GFP) promoter. Using this strategy,
enriched populations of restricted progenitors or mature cell
types can be generated for transplantation. Immortalization of
human neural progenitors through the retrovirally-induced
expression of human telomerase reverse transcriptase may be
critical in allowing these cells to be expanded sufficiently to be
clinically relevant in neurological disease [21].
ES cells can proliferate indefinitely in vitro while retaining
the ability to differentiate into all somatic cells. Murine ES cells
were first isolated in 1981 [22] and cultured with leukemia
inhibitory factor (LIF) and/or a feeder layer of mitotically-
inactivated mouse embryonic fibroblasts in an undifferentiated
state [23]. ES cells differentiate spontaneously into multicellular
aggregates in the absence of LIF or removal of feeder layers,
termed embryoid bodies since they resemble early post-
implantation embryos. Within the nervous system, ES cells are
responsive to environmental cues upon transplantation and
adopt a cellular fate that is appropriate to the transplanted region.
Nevertheless, the dependence upon environmental cues to direct
stem cells, precludes the efficient generation of neurons in non-
neurogenic regions of the CNS [24–26]. The direct differentia-
tion of ES cells efficiently and specifically into a particular
mature cell type can be achieved in some cases, although much
work is still required this field. Several transcription factors and
developmental morphogens have been demonstrated to regulate
differentiation of ES cells to specific cell types [27–30].
Identification and separation of differentiated cells from residual
ES cells or other mature cell types can be achieved through the
expression of fluorescent markers [31] or drug resistance genes
under control of a cell-type specific promoter [32]. A mixture of
oligodendrocytes and astrocytes can be produced from ES cells
through treatment of specific growth factor combinations
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oligodendrocytes [36] or astrocytes [31] can be preferentially
enriched using other protocols.
4. The potential of stem cells in neurological diseases
The potential uses of stem cells in neurological diseases
may be classified into several categories. First, stem cells can
be utilized as a biological tool to understand neurological
disease. For example, the ability to isolate and expand ES cell
lines from a variety of genetically-defined animal models of
human disease and to efficiently direct ES cells toward
particular neural lineages allows researchers to examine the
abnormal cellular and molecular processes in these cells. The
goal is to create a cell-culture model of human disease which
could be a useful tool in understanding disease and in
screening potential therapies. Second, the potential of
endogenous stem cells present in the mammalian nervous
system can be harnessed and expanded to repair damaged
tissue. Endogenous stem cells exist within multiple regions of
the mammalian nervous system and yet, unlike stem cells in
other tissues, do not contribute to tissue repair. By under-
standing the cues that guide endogenous stem cell function,
researchers may be able to modulate this function thus
leading to functionally-relevant neural tissue repair. Finally,
stem cells or committed progenitors derived from stem cells
can be transplanted into the injured nervous system as a
therapeutic strategy. Transplanted cells may serve a therapeu-
tic role in a number of ways (presented in order of increasing
complexity): they may provide trophic support to host cells,
slow a degenerative process, facilitate axonal growth or glial
function, secrete neurotransmitters deficient in the host,
differentiate into oligodendrocytes and myelinate host axons,
or differentiate into neurons and either form neuronal
connections across disconnected populations or replace
damaged neuronal circuits.
5. Generation of motor neurons
Motor neurons can be generated efficiently by exposing
mouse ES cells to retinoic acid and to the developmental
morphogen sonic hedgehog (Shh) or chemical agonists of
Shh. In this paradigm, retinoic acid serves both to neuralize
and to establish a caudal positional identity for the pluripotent
ES cells. Shh further specifies a ventral positional identity,
and in response, many ES cells initiate a motor neuron-
specific transcriptional pattern [37] and acquire immunohis-
tochemical and electrophysiological features of mature
neurons [38]. ES cell-derived motor neurons transplanted
into embryonic chick spinal cord extend axons into the
periphery and form neuromuscular junctions [39]. In vivo
transplantation of motor neuron-committed ES cells into adult
paralyzed rats results in the generation of several thousand
new motor neurons following transplantation, several hun-
dreds of which extended axons from the spinal cords into the
peripheral nervous system [40]. More recently, these studies
have been repeated and extended using human ES and neuralstem cells by a variety of strategies. Cholinergic neurons can
be generated from human ES cells (K048 cell line) [41] and
from fetal human NSCs [42]. When transplanted into the
adult mammalian nervous system, these cells may occasion-
ally form neuromuscular junctions with host muscle and
facilitate partial functional recovery [43]. However, it remains
unclear whether the re-innervation of host muscle was
relevant to the functional recovery.
6. Non-neuronal cellular replacement in motor neuron
diseases
Although much attention has been given to replacement of
upper and/or lower motor neurons in motor neuron diseases,
it is increasingly clear that dysfunction of other cell types
(i.e., glial cells or muscle) contributes to disease and
therefore, that providing a normally functioning population
of these cell types may be therapeutically beneficial [44–46].
In ALS, there is astrocytic and microglial proliferation in the
cortex and spinal cord and pro-inflammatory factors thought
to function in neurodegenerative pathways have been
identified in human ALS patients and in animal models of
ALS. But whether microglia and astrocyte activation is a
cause of neuronal loss or is secondary to neuronal loss is
under debate. However, it is clear that astrocytes modify
neurogenesis in the CNS [26] and that astrocytes derived
from human neural progenitors decrease excitotoxic injury of
motor neurons by expressing the glutamate-aspartate trans-
porter [47]. In addition, human neural precursor cell (hNPC)-
derived glia may provide critical metabolic reagents to motor
neurons in energy crisis [48]. Transplantation of NSCs in
certain paradigms results in primarily transplant-derived
astrocytes and occasional oligodendrocytes [49] suggesting
that the positive effects are mediated either by trophic support
provided by astrocytes [50]or by remyelination of axons by
graft-derived oligodendrocytes [51]. In some studies, NSCs
have been engineered to release glial cell-derived neuro-
trophic factor (GDNF) [52] prior to transplantation and have
been shown to facilitate improve outcome in SOD1G93A rats
[53]. Hofstetter et al. showed that NSCs improve recovery of
motor function in the treatment of spinal cord injury, but
allodynia occurred in unaffected forepaws [54]. However,
proper control of differentiation by transduction with
neurogenin-2, a transcription factor that promotes oligoden-
drocyte differentiation, increased remyelination in the injured
area and allowed recovery of hindlimb locomotor function
and hindlimb sensory responses. Human NSCs grown as
neurospheres were able to remyelinate host neurons in both
spinal cord injured animals and in myelin-deficient shiverer
mice [55].
In addition to glial cells, muscle plays an important role in
providing guidance and cues to the developing motor neurons
and in providing trophic support to maintain motor neuron
and axon function [56,57]. Further, since denervated skeletal
muscle exhibits reduced secretion of neurotrophins including
brain derived neurotrophic factor (BDNF), neurotrophin-3
(NT-3), nerve growth factor (NGF), cardiotrophin-1 (CT-1),
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that accelerated axonal loss and dysfunction is due to failed
muscle trophic support of motor neurons. For that reason,
several groups have suggested that myoblast transplantation
may be a relevant target in motor neuron diseases. It has been
suggested that muscle could be a therapeutic target in the
treatment of SMA [58]. Myoblasts modified to secrete GDNF
have been shown to prevent motor neuron loss in a model of
ALS [59].
7. Cellular therapies to deliver trophic factors in motor
neuron disease
Neurotrophins and other trophic factors serve functions such
as differentiation, maintenance of function, synaptic plasticity,
survival and regeneration. They act through the high affinity
receptors that include tyrosine kinases (trks; trkA, B and C) and
the low affinity receptors such as p75NTR. It has been shown
that the trkB neurotrophic receptor shows lowered phosphor-
ylation in the spinal cord of patients with ALS [60]. This raises
the possibility that transplantation of stem cells that over-
express trophic factors would be beneficial in motor neuron
diseases. Delivery of neurotrophins have been hindered by
limited bio-availability, inability of neurotrophins to cross the
blood–brain barrier, by toxicity of the neurotrophins in non-
neuronal sites and by the relative short half-life of the
neurotrophins. This has been circumvented to some degree by
the use of viral vectors to introduce the trophic factors to the site
of injury. However, delivery concerns and in some cases the
possibility of insertional mutagenesis may continue to limit the
use of viral vectors in this regard. Further, though viral vectors
may introduce a single trophic factor, greater benefit may be
achieved by the use of multiple neurotrophins [61], a strategy
that is optimally achieved by the use of cellular therapies.
Therefore, one potential research approach, combining both
viral-based gene therapy and cellular therapies, would be to
manipulate stem cells ex vivo followed by transplantation of
appropriately-characterized cells. This approach could reduce
the risks associated with viral and cellular therapies since the
growth characteristics of the cells, insertion site of the virus and
ability to regulate transgenes could be determined prior to
transplantation [51–53].
Several specific trophic factors have been shown to be
effective in motor neuron diseases as discussed below:
7.1. GDNF
Glial cell-derived neurotrophic factor (GDNF) is one of the
most potent neurotrophic factors and has been studied
extensively in mouse models of neurodegenerative diseases
such as Parkinson's disease and ALS. GDNF is produced by
glial cells of the CNS as well as the peripheral nervous system,
such as oligodendrocytes, astrocytes and Schwann cells. GDNF
exerts its effects by acting on both astrocytes and motor
neurons. Several studies have indicated that GDNF protects
mouse motor neurons from injury-induced cell death [62].
GDNF can prevent loss of choline acetyltransferase (ChAT)expression in facial motor neuron following axotomy [63].
GDNF has been introduced into animal models of ALS and
Parkinson's disease in several ways. GDNF introduction into
the muscle of SOD1 mutant mice travels retrogradely to spinal
motor neurons and thus increases survival [64] although this
study has so far failed to be replicated in larger animals (Jeff
Rothstein, personal communication). In recent studies, hNPC
isolated from post-mortem fetal brain tissue, were used to
deliver GDNF in a rat model of ALS [53] and to Parkinsonian
rodents and aged primates [65]. These hNPCs were “mini-
pumps” for GDNF and had earlier been shown to generate both
astrocytes and neurons following transplantation into the CNS
[66]. These hNPCs were both a source of glial replacement and
a trophic factor delivery. However, it has been recognized that
GDNF in many regions of the body will have undesired side
effects and there is a need for targeted localized introduction
[67]. In addition, the outcomes of several clinical trials with
GDNF have proven to be largely not beneficial. GDNF in
conjunction with other neurotrophins has proved to be more
beneficial [61].
7.2. IGF-1
Insulin growth factor 1 (IGF-1) is a potent neurotrophic
factor produced mainly by oligodendrocytes during develop-
ment [68] and by Schwann cells [69] following injury. Muscles
innervated by motor neurons have also been shown to be a
source of IGF-1 (mIGF-1) [56]. IGF-1 receptors are expressed
on motor neurons, muscle and glia [70,71]. IGF-1 increased
motor neuron survival both in vitro [72] and in vivo in an
axotomy-induced cell death model in rodents [73]. IGF-1 was
also shown to increase nerve regeneration, axonal sprouting and
muscle innervation in vitro [74]. In addition to its neurotrophic
effect on neurons, IGF-1 plays an important role during the
development of myelinating cells such as Schwann cells [75]
and oligodendrocytes [76]. Motor neuron survival was
significantly enhanced when co-cultured with astrocytes in
combination with IGF-1 [72]. In addition to providing trophic
support, IGF-1 by itself inhibits apoptosis [77]. In the wobbler
mouse model of motor neuron disease, IGF-1 effect was
potentiated with administration of glycosaminoglycans along
with IGF-1 [78]. In an animal model of ALS, IGF-1 and GDNF
acted additively to enhance motor neuron survival [61]. Free
IGF-1 is reduced and specific IGF-1 binding proteins are
abnormally regulated in ALS patients [71,79] thus suggesting
intrathecal delivery of IGF-1 to be useful in therapy. However,
clinical studies involving administration of IGF-1 in patients
with ALS showed minimal effect [80].
7.3. VEGF
Vascular endothelial growth factor (VEGF) is a cytokine that
has a dual role in neuroprotection and angiogenesis. Low level
of VEGF has been found in the cerebrospinal fluid (CSF) of
ALS patients [81] and ALS patients have reduced cerebral
blood flow and hypoxia [82,83]. Terry et al. suggested a
correlation between two VEGF promoter haplotypes and
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several mouse models of ALS as well as a mouse model of
spinal and bulbar muscular atrophy [85]. VEGF therapy has
proved to be beneficial in several models of motor neuron
disease [86–88]. VEGF promotes survival of motor neurons in
vitro [89]. VEGF has been shown to enhance angiogenesis and
improve neuronal regeneration following axotomy. Hobson et
al. showed that following sciatic nerve axotomy, VEGF induced
neurogenesis [90]. In addition, VEGF was shown to induce the
proliferation of neuronal precursors that gave rise to several
neurons and astrocytes [91]. Biologically active VEGF
delivered into the CSF of mutant SOD1 transgenic mice
alleviated motor neuron damage and led to improvement of
motor function [88]. Hypoxia resulted in increased VEGF
production in tissues and deletion of the hypoxia response
element on the VEGF promoter resulted in motor neuron
disease in mice [92]. The ability of VEGF to increase blood
flow, enhance local oxygen delivery and thus improve overall
motor neuron health, places it as a leading candidate for therapy
in humans.
7.4. HGF
Hepatocyte growth factor (HGF) is a relatively new
addition to the list of beneficial neurotrophins. It is a novel
neurotrophic factor and is comparable in effect to GDNF [93].
HGF was shown to play several roles during the development
of motor neurons, either alone or in combination with other
neurotrophins such as CNTF [94]. Over-expression of HGF in
a transgenic mouse model of ALS was able to retard disease
progression and prolong survival by preventing caspase
mediated cell death of motor neurons and by maintaining
the levels of glial specific glutamate transporter (EAAT2/GLT-
1) in reactive astrocytes [95].
7.5. CT-1
Cardiotrophin 1 (CT-1) belongs to the IL-6 family and is a
muscle derived trophic factor. CT-1 has shown neuroprotective
effects in several models of ALS and even SMA. CT-1 was
shown to protect spinal motor neurons in culture and prevented
axotomy-induced cell death of sciatic neurons in rats [96]. It has
shown myotrophic and neurotrophic ability in the wobbler
mouse model of motor neuron disease [97]. Intramuscular
delivery of a CT-1 adenoviral gene protected neuromuscular
degeneration in pmn mice [98] and increased survival in an
animal model of SMA [99].
7.6. LIF
Leukaemia inhibitory factor (LIF) is a member of the
cytokine family that includes CNTF, IL-6, CT-1, IL-11, and
signals through gp130. LIF was shown to play a role in motor
[100,101] and sensory neuron survival [102,103]. It stimulated
myoblast proliferation [104] and reduced denervation induced
muscle atrophy [105]. It entered clinical trial in 1998 [106].
However, recent studies in animal models of ALS haveindicated that administration of LIF does not have effect on
neuronal protection or survival [107,108].
7.7. CNTF
Ciliary neurotrophic factor (CNTF) is produced by glial
cells and is similar to CT-1. It is synthesized post-natally and
is not expressed during CNS development. Non-neuronal
cells that were engineered to produce CNTF when intro-
duced into an axotomy model of motor neuron disease were
able to rescue damaged motor neurons [109]. CNTF
generated by this model was given intrathecally to patients
with ALS with no side effects but with minimum improve-
ment in clinical status [110]. Clinically, CNTF was reduced
in spinal cord of patients with ALS suggesting its importance
in the development of the disease [111]. However, in a
recent study by Al-Chalabi et al. involving 400 patients with
ALS, there was no correlation between CNTF and disease
progression [112].
7.8. BDNF
Brain derived neurotrophic factor (BDNF) is a muscle
derived neurotrophic factor. BDNF supports motor neuron
survival by preventing neuronal nitric oxide synthase produc-
tion and ultimately motor neuron apoptosis [113]. It can also
prevent glutamate induced neurotoxocity [114,115]. In a
glutamate mediated in vitro model of motor neuron disease,
BDNF was not capable of protecting motor neurons, unlike
other neurotrophic factors such as GDNF and IGF-1 [116]. In
clinical studies, BDNF introduced intrathecally was well-
tolerated, showed very few side effects but had very little
clinical effect [117,118].
7.9. NT-3
Neurotrophin-3 (NT-3) belongs to the same family as NGF
and BDNF. In vitro, NT-3 has potent neuron-protective effects
on cultured motor neurons [119,120] and NT-3 can be
transported retrogradely through motor neurons [121]. Intra-
muscular injection of an adenovirus encoding NT-3 increased
survival of pmn mice, reduced motor neuron loss and improved
neuromuscular junction activity [122]. NT-3 uses the trkC
receptor which is not abundantly expressed in normal or ALS
spinal cord motor neurons [123]. This might limit its use as a
therapeutic agent in ALS.
8. Summary of trophic support strategies
Intrathecal administration of trophic factors in the clinic
has met with limited success. Lack of bio-availability and
short half life of the trophic factors are the primary reasons
for this discrepancy from in vitro models where these trophic
factors were shown to play dramatic roles. Clinical efficacy
has been slightly improved by the introduction of viral
vectors and non-neuronal cells capable of continuously
generating these neurotrophic factors. However, stem cells
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the most feasible option. These stem cells, regardless of
whether they are adult NSC or ES cells, will have the added
advantage of being able to develop into numerous cell types
such as glia and neurons. They can be engineered to produce
these neurotrophins that will support dying neurons as well as
the generation of new ones. In addition, stem cells can be
engineered to express higher levels of certain types of
receptors that will enable signaling of neurotrophic factors
that will not be possible otherwise.
9. Regulatory concerns as stem cell therapies enter
the clinic
Since animal studies have increasingly shown that stem cells
have promise as a potential therapy in neurologic diseases, there
needs to be an appreciation of the regulatory issues that guide
the translation of these findings to clinical use. The Food and
Drug Administration (FDA) along with Institutional Review
Boards and other oversight bodies will be the final arbiters of
clinical trials carried out in the United States. The FDA has had
several discussions with scientists, biotechnology companies
and with interested patient advocacy groups since the late 1990s
in anticipation of applications for human trials using stem cells.
It has issued a series of guidelines for the use of stem cells in
human patients, most recently amended on November 24th,
2004 (Federal Register, Volume 69, number 226, November 24
2004).
The FDA recognized the following in establishing a
framework for stem cell trials: “All cellular products present
many complex issues not encountered with other classes of
biologicals. These products can easily support the growth of
many pathogenic microorganisms and cannot be sterilized.
Moreover, they quite likely will be administered to very
sensitive sites, such as the CNS. Thus, efforts to minimize risks
(e.g., stringent microbiological controls) and to justify these
risks (e.g., a rationale for human use supported by appropriate
animal studies) are of special importance” (Biologics Response
Modifiers Advisory Committee Meeting 2000).
The oversight of the FDAwith regard to stem cell therapies is
likely to fall into several areas [105].
9.1. Process controls
Process controls refers to defining the process of generating
the stem cell reagent that will be used in patients. The stem cells
must be qualified which means that the product to be introduced
into patients must be sequenced for the presence of retroviruses,
screened for infectious pathogens, historical profiled, and the
purity of the stem cell population must be determined. With
regard to potential infectious contaminants, the purpose is to
prevent using cells that could carry infectious diseases such as
human immunodeficiency virus, other retroviruses and hepatitis
viruses. This risk is largely similar to that from allogeneic
transplantation (i.e., organ transplantation) and is not unique to
stem cells. However, since all of the human ES lines approved
for federal funding in the United States have been derived usingmouse feeder layers, the FDA has stated that such stem cells
would be governed by regulatory requirements for xenotrans-
plantation (Schewtz BA. Acting Principal Deputy Commis-
sioner. Letter on Stem Cells to Senatory Kennedy. Web site:
Department of Public Health, US FDA, 5 September 2001.
URL: www.fda.gov/oc/stemcells/kennedyltr.html). Historical
profiling refers to identifying the entirety of all reagents that
have come in contact with the cells. The FDA Biological
Response Modifiers Advisory Committee (BRMAC) has stated
any stem cell line used in human trials must be completely
traceable. Further, each of the reagents that have come in
contact with the cells needs to have a quality assurance and
quality control certification. Purity of the cells must be
confirmed; there can be no undifferentiated embryonic stem
cells in the transplant population, which may cause tumors. This
can be accomplished by checking for predetermined markers
such as SSEA4, OCT4, and TRA81. Genetic stability needs to
be determined by karyotypic analysis. All of these requirements
are included in the guidelines for Current Good Tissue Practice.
The FDA has recently published guidelines that govern the
methods used in, and the facilities and controls used for human
cell, tissue and cellular and tissue-based products (HCT/Ps).
These guidelines also include rules on recordkeeping and the
establishment of a quality program, and labeling, reporting,
inspection and enforcement that will apply to manufacturers of
those HCT/Ps (Federal Register, Volume 69, number 226,
November 24 2004).
9.2. Preclinical pharmacology and toxicology
Preclinical testing needs to provide data regarding the
potential of stem cells to affect local and/or distant tissues
within the transplanted host. There are four principle areas that
the FDA BRMAC has identified as critical parameters in
preclinical toxicology studies: possibility of tumor formation,
inappropriate cellular differentiation, cell migration and host
immune responses. The most obvious concern is that the
transplanted cells may cause tumors to form within the host.
Within the transplant population, a small fraction of cells may
be undifferentiated or inadequately differentiated cells could
become tumors. Although it is not clear that tumorigenesis
studies need to be done in primates, it is clear that at least 1 year
of follow up will be required to evaluate for the possibility of
tumor formation. The possibility of cell transplantation resulting
in neoplasia was underscored in several X-linked severe
combined immunodeficiency patients recently treated in a
human gene therapy trial. In the trial, patient bone marrow cells
were engineered to express the deleted gene by the use of a
retroviral vector and then re-implanted in the patient. However,
in a substantial proportion of patients, the retrovirus integrated
into the host genome near a proto-oncogene, causing leukemia
[124]. Therefore, genetically modified stem cells and likely
even partially differentiated stem cells may pose a risk of tumor
formation.
Even if the cells fail to form tumors, differentiating into an
inappropriate tissue/cell type could be equally dangerous and
this risk must be defined in preclinical testing. For example, if
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paralyzed patient inappropriately differentiate into cartilage
producing cells, the clinical deficit could be worsened. Also in
preclinical testing, studies must define the extent of transplant
migration (bio-distribution) both within the target tissue and in
remote tissues. One way is to use Reverse Transcription
Polymerase Chain Reaction for human markers on isolated
organs following transplantation.
Finally, toxicity studies will require an evaluation of organ
and tissue function and an assessment of tissue injury after
transplantation. Since the cells are foreign to the body, there is
likely to be an immune response and that immune response may
disturb an organ's normal function. Studies will be required to
assess activation of the host immune system and define the
presence of rejection. Histologic studies will also need to define
whether any immune activation has altered the tissue morpho-
logy and/or induced bystander host cells around the transplant.
9.3. Human transplantation methods/standard operating
procedure
The methods of transplantation must also be established.
While the transplantation methods for rodents are well-known,
those for humans are not as well understood. The maximum
volume and number of cells that can be transplanted must be
determined. Since the pre-clinical research is usually conducted
on rodents, the proportion of cells required to treat humans must
be translated from these studies. The number of injection sites
also needs to be determined. Equipment needs must also be
assessed and this equipment may be subject to additional
regulatory requirements prior to conducting the trial. For
example, syringes, infusion pumps, stereotaxic equipment will
all be required for transplantation, and though some of this
equipment is used routinely within clinical neurosurgical
practices, the application to stem cell clinical trials will require
additional study. Surgical teams will need to be assembled andFig. 1. Differentiation of stem cell into neuronal type and applications of cellular th
neuronal phenotype in response to a variety of factors. Distinct combinations of tr
effectively form selective connections with the appropriate target tissue with a combi
hedgehog; RA, retinoic acid; Fgf8b, fibroblast growth factor 8b; Dkk1, Dickkopf-1well trained in every aspect of the transplantation. The hospitals
or clinics that are going to be selected to conduct the clinical
trials must be determined. It is essential that these hospitals have
an adequate subject population and the capacity to appropriately
care for the stem cells. All of these methods must be compiled
into a set of standard operating procedures in order to
standardize all of the procedures used.
9.4. Evaluation/termination
The termination of the treatment must be determined should
a serious adverse event occur. Although it is clear that, unlike in
a conventional drug therapy, the cell-based therapy cannot be
retrieved or stopped, there are several potential strategies to
mitigate the potential deleterious effects of transplanted cells.
First, immunosuppression could be stopped although, as noted
above, this strategy invites potential bystander host tissue
damage as the host immune system rejects the transplanted
cells. Secondly, the transplanted cells could have an engineered
suicide gene (such as HSV-tk) which would render the cells
susceptible to a systemically administered drug (such as
gancyclovir). However, the efficiency of cellular suicide and
target organ penetration by the systemic drug may be variables
in this approach. Further, many of these approaches eradicate
only dividing cells and thus any post-mitotic cells will be
resistant to drugs such as gancyclovir.
9.5. Steps forward
Because of the complexity involved in translating stem cell
biology into a therapeutic reality, the amount of money required
is daunting. The National Institutes of Health has a history of
funding early pre-clinical development. Translation into the
clinic is expensive and risky, leading scientists to rely on
industry funding for the translation and clinical trials. The
magnitude of the cost is astounding; hundreds of millions oferapies in motor neuron disease. Cultured stem cells can be differentiated into
anscription factors regulate the neuronal differentiation. Transplanted neurons
nation of trophic factors and inhibition of myelin-associated proteins. Shh, sonic
.
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a huge role in whether the science actually gets to the clinical
trial stage.
There are some recent activities that are helping to advance
this research. A phase 1 trial using human fetal tissue has been
conducted and was found to be safe in the United States in
patients with chronic spinal cord injury [125]. Additionally,
there are several planned Phase 1 trials of cell-based interven-
tions for neurologic conditions. Athersys Inc. (Ohio, USA)
plans to carry out a clinical trial using the Multistem™ platform
based on the multipotent adult progenitor cell technology in
Hurler's disease, a lethal pediatric syndrome caused by enzyme
deficiency. BrainStorm Cell Therapeutics (Israel) plans to carry
out a trial of bone-marrow derived cells in Parkinson's disease.
Geron (CA, USA) plans to carry out a clinical trial using human
ES cells in patients with acute spinal cord injury. And Living
Cell Technologies, Ltd (Australia, New Zealand, Italy, RI USA)
will study porcine choroids plexus brain cells encased in a bio-
polymer capsule to avoid rejection in patients with Huntington's
disease.
10. Conclusions
Recent advances in understanding stem cell biology have
generated great excitement that these cells represent a potential
therapy for a wide variety of disorders as depicted in Fig. 1.
However, both biologic and political hurdles remain until it is
proven that stem cells can be a therapeutic strategy in
neurologic diseases. Ultimately, we may attain a realistic
understanding that stem cells will be clinically used not as a
“cure-all” but as one part of a therapeutic armamentarium. Some
patients may get better. But like with any therapy, some patients
may get worse. The key, however, will be in applying the right
cell type to the right disease and conveying the right amount of
expectation to the patient; only then will we see stem cells as a
clinically relevant tool for the neurologist in the future.
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